Argenica Therapeutics Ltd (AGN) - Total Liabilities
Based on the latest financial reports, Argenica Therapeutics Ltd (AGN) has total liabilities worth AU$1.76 Million AUD (≈ $1.24 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore AGN net assets growth trend to track the company's year-over-year net asset growth rate.
Argenica Therapeutics Ltd - Total Liabilities Trend (2019–2024)
This chart illustrates how Argenica Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data.
Argenica Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Argenica Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EcoBio Holdings Co. Ltd
KQ:038870
|
Korea | ₩34.64 Billion |
|
ES Australia Israel Holdings Ltd
TA:AUIS
|
Israel | ILA423.97 Million |
|
Concord Medical Services Holdings
NYSE:CCM
|
USA | $4.70 Billion |
|
Energys Group Limited Ordinary Shares
NASDAQ:ENGS
|
USA | $10.36 Million |
|
Samyoung S&C Co. Ltd.
KQ:361670
|
Korea | ₩2.85 Billion |
|
CNPLUS Co. Ltd.
KQ:115530
|
Korea | ₩47.39 Billion |
|
LQwD FinTech Corp
V:LQWD
|
Canada | CA$42.45K |
|
CMX GOLD+SILVER CORP.
F:6GS
|
Germany | €733.54K |
Liability Composition Analysis (2019–2024)
This chart breaks down Argenica Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Argenica Therapeutics Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Argenica Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Argenica Therapeutics Ltd (2019–2024)
The table below shows the annual total liabilities of Argenica Therapeutics Ltd from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | AU$3.80 Million ≈ $2.69 Million |
+56.66% |
| 2023-12-31 | AU$2.43 Million ≈ $1.72 Million |
+29.46% |
| 2022-12-31 | AU$1.87 Million ≈ $1.33 Million |
+154.71% |
| 2021-12-31 | AU$735.91K ≈ $520.70K |
+72.86% |
| 2020-12-31 | AU$425.72K ≈ $301.22K |
+18.50% |
| 2019-12-31 | AU$359.26K ≈ $254.20K |
-- |
About Argenica Therapeutics Ltd
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Aus… Read more